Literature DB >> 33682583

Chlamydia trachomatis vaccines for genital infections: where are we and how far is there to go?

Luis M de la Maza1, Toni L Darville2, Sukumar Pal1.   

Abstract

INTRODUCTION: Chlamydia trachomatis is the most common sexually transmitted bacterial pathogen in the world. Antibiotic treatment does not prevent against reinfection and a vaccine is not yet available. AREAS COVERED: We focus the review on the progress made of our understanding of the immunological responses required for a vaccine to elicit protection, and on the antigens, adjuvants, routes of immunization and delivery systems that have been tested in animal models. PubMed and Google Scholar were used to search publication on these topics for the last 5 years and recent Reviews were examined. EXPERT OPINION: The first Phase 1 clinical trial of a C. trachomatis vaccine to protect against genital infections was successfully completed. We expect that, in the next five years, additional vaccine clinical trials will be implemented.

Entities:  

Keywords:  Chlamydia muridarum; Chlamydia trachomatis; adjuvants; antigens; delivery systems; immunization; mouse model; routes of immunization; sexually transmitted infections; vaccines

Mesh:

Substances:

Year:  2021        PMID: 33682583      PMCID: PMC8934038          DOI: 10.1080/14760584.2021.1899817

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  92 in total

1.  Discovery of Blood Transcriptional Endotypes in Women with Pelvic Inflammatory Disease.

Authors:  Xiaojing Zheng; Catherine M O'Connell; Wujuan Zhong; Uma M Nagarajan; Manoj Tripathy; De'Ashia Lee; Ali N Russell; Harold Wiesenfeld; Sharon Hillier; Toni Darville
Journal:  J Immunol       Date:  2018-03-12       Impact factor: 5.422

Review 2.  Update on Chlamydia trachomatis Vaccinology.

Authors:  Luis M de la Maza; Guangming Zhong; Robert C Brunham
Journal:  Clin Vaccine Immunol       Date:  2017-04-05

3.  VACCINES. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells.

Authors:  Georg Stary; Andrew Olive; Aleksandar F Radovic-Moreno; David Gondek; David Alvarez; Pamela A Basto; Mario Perro; Vladimir D Vrbanac; Andrew M Tager; Jinjun Shi; Jeremy A Yethon; Omid C Farokhzad; Robert Langer; Michael N Starnbach; Ulrich H von Andrian
Journal:  Science       Date:  2015-06-19       Impact factor: 47.728

4.  CD4+ T cells and antibody are required for optimal major outer membrane protein vaccine-induced immunity to Chlamydia muridarum genital infection.

Authors:  Christina M Farris; Sandra G Morrison; Richard P Morrison
Journal:  Infect Immun       Date:  2010-07-26       Impact factor: 3.441

5.  Induction of partial immunity in both males and females is sufficient to protect females against sexual transmission of Chlamydia.

Authors:  C P O'Meara; C W Armitage; A Kollipara; D W Andrew; L Trim; M B Plenderleith; K W Beagley
Journal:  Mucosal Immunol       Date:  2015-12-09       Impact factor: 7.313

6.  A Recombinant Chlamydia trachomatis MOMP Vaccine Elicits Cross-serogroup Protection in Mice Against Vaginal Shedding and Infertility.

Authors:  Delia F Tifrea; Sukumar Pal; Luis M de la Maza
Journal:  J Infect Dis       Date:  2020-01-02       Impact factor: 5.226

7.  Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results.

Authors:  L Weström; R Joesoef; G Reynolds; A Hagdu; S E Thompson
Journal:  Sex Transm Dis       Date:  1992 Jul-Aug       Impact factor: 2.830

8.  Improved protection against Chlamydia muridarum using the native major outer membrane protein trapped in Resiquimod-carrying amphipols and effects in protection with addition of a Th1 (CpG-1826) and a Th2 (Montanide ISA 720) adjuvant.

Authors:  Delia F Tifrea; Sukumar Pal; Christel le Bon; Melanie J Cocco; Manuela Zoonens; Luis M de la Maza
Journal:  Vaccine       Date:  2020-04-30       Impact factor: 3.641

9.  A Multi-Component Prime-Boost Vaccination Regimen with a Consensus MOMP Antigen Enhances Chlamydia trachomatis Clearance.

Authors:  Alexander Badamchi-Zadeh; Paul F McKay; Bette T Korber; Guillermo Barinaga; Adam A Walters; Alexandra Nunes; João Paulo Gomes; Frank Follmann; John S Tregoning; Robin J Shattock
Journal:  Front Immunol       Date:  2016-04-28       Impact factor: 7.561

10.  Intramuscular Priming and Intranasal Boosting Induce Strong Genital Immunity Through Secretory IgA in Minipigs Infected with Chlamydia trachomatis.

Authors:  Emma Lorenzen; Frank Follmann; Sarah Bøje; Karin Erneholm; Anja Weinreich Olsen; Jørgen Steen Agerholm; Gregers Jungersen; Peter Andersen
Journal:  Front Immunol       Date:  2015-12-16       Impact factor: 7.561

View more
  4 in total

1.  Overexpression of the Bam Complex Improves the Production of Chlamydia trachomatis MOMP in the E. coli Outer Membrane.

Authors:  Dung T Huynh; Wouter S P Jong; Gregory M Koningstein; Peter van Ulsen; Joen Luirink
Journal:  Int J Mol Sci       Date:  2022-07-02       Impact factor: 6.208

2.  The inclusion membrane protein IncS is critical for initiation of the Chlamydia intracellular developmental cycle.

Authors:  María Eugenia Cortina; R Clayton Bishop; Brittany A DeVasure; Isabelle Coppens; Isabelle Derré
Journal:  PLoS Pathog       Date:  2022-09-09       Impact factor: 7.464

Review 3.  Chlamydia trachomatis as a Current Health Problem: Challenges and Opportunities.

Authors:  Rafaela Rodrigues; Carlos Sousa; Nuno Vale
Journal:  Diagnostics (Basel)       Date:  2022-07-25

4.  Chlamydia trachomatis Polymorphic Membrane Proteins (Pmps) Form Functional Homomeric and Heteromeric Oligomers.

Authors:  Alison Favaroni; Johannes H Hegemann
Journal:  Front Microbiol       Date:  2021-07-19       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.